IVAX Corporation is a multinational company engaged in the research, development, manufacturing and marketing of branded and generic pharmaceuticals and veterinary products in the U.S. and internationally. Our Company has two primary missions: to provide high-quality pharmaceuticals that improve the health of our customers, and to operate as an ethical and honorable corporate citizen. We work to fulfill these missions by enhancing our existing products, as well as by continually developing important new medications to treat a wide variety of illnesses. We believe that IVAX has one of the strongest pipelines in the generic pharmaceutical sector with 43 Abbreviated New Drug Applications (ANDAs) pending with the U.S. Food and Drug Administration (FDA) as of March 31, 2004 and large numbers of applications pending in other countries in which we operate. We also have one of the strongest proprietary drug pipelines among our peers, with product candidates in advanced phases of clinical trials to treat respiratory, oncologic, central nervous system, gastrointestinal, urological disorders and endocrinologic disorders. IVAX is headquartered in Miami, Florida, has direct operations in 36 countries, and markets products in more than 80 countries around the globe.